Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Novo Nordisk Says Wegovy Cuts Heart Risk by 57% Compared With Eli Lilly’s Obesity Drug

Summary by BizToc
The Entire Business World on a Single Page with the Web's Most Comprehensive One-Stop Finance News Hub.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

3 Articles

BizTocBizToc

Novo Nordisk Says Wegovy Cuts Heart Risk by 57% Compared With Eli Lilly’s Obesity Drug

The Entire Business World on a Single Page with the Web's Most Comprehensive One-Stop Finance News Hub.

Read Full Article
Clinical Trials ArenaClinical Trials Arena
Reposted by
pharmaceutical-technology.compharmaceutical-technology.com

ESC 2025: Novo Nordisk’s Wegovy superior to Zepbound in reducing CV events

In the real-world trial, Novo Nordisk's Wegovy showed a significant reduction in CV events compared to Eli Lilly’s Zepbound.The post ESC 2025: Novo Nordisk’s Wegovy superior to Zepbound in reducing CV events appeared first on Clinical Trials Arena.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

pharmaceutical-technology.com broke the news in on Monday, September 1, 2025.
Sources are mostly out of (0)

Similar News Topics

Eli Lilly icon

Eli Lilly

News
For You
SearchBlindspotLocal